Recently, the capital siphoning effect brought about by the adjustment of technology stocks has gradually subsided, market capital has been redistributed, and the net worth of pharmaceutical-themed funds has clearly recovered. However, unlike the successful performance of optical modules and semiconductor circuit funds, the pharmaceutical sector's internal revenue differentiation is very obvious. It is also a pharmaceutical-themed fund. Some products have yielded close to 50% since 2026, but there are also many pharmaceutical funds that are still losing money during the year. A number of industry insiders have also judged that in public investment in the innovative drug circuit, the ability to select individual stocks will determine the income elasticity of pharmaceutical funds. Against the backdrop of weakening industry beta, the investment advantage of active equity funds in the pharmaceutical circuit is gradually increasing.

Recently, the capital siphoning effect brought about by the adjustment of technology stocks has gradually subsided, market capital has been redistributed, and the net worth of pharmaceutical-themed funds has clearly recovered. However, unlike the successful performance of optical modules and semiconductor circuit funds, the pharmaceutical sector's internal revenue differentiation is very obvious. It is also a pharmaceutical-themed fund. Some products have yielded close to 50% since 2026, but there are also many pharmaceutical funds that are still losing money during the year. A number of industry insiders have also judged that in public investment in the innovative drug circuit, the ability to select individual stocks will determine the income elasticity of pharmaceutical funds. Against the backdrop of weakening industry beta, the investment advantage of active equity funds in the pharmaceutical circuit is gradually increasing.